CYSTINOSIS RESEARCH NETWORK INC
Balance Sheet
Fiscal Year Start:
Jan 1
Assets in 2024 (Year End)
$604,986
Cash & Equivalents
>99%
Receivables (Non-Related)
0%
Related-Party Receivables
0%
Inventories
0%
Prepaid Expenses
0%
Investments
0%
Property, Plant, & Equipment (net)
0%
Other Assets
0%
Liabilities in 2024 (Year End)
$43,460
Payables & Accruals
71%
Deferred Revenue
29%
Grants Payable
0%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Other Liabilities
0%
Assets
2023
2024
Change
Cash & Equivalents
$298,290
$604,986
+103%
Receivables (Non-Related)
-
-
-
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
-
-
-
Investments
-
-
-
Property, Plant, & Equipment (net)
-
-
-
Other Assets
-
-
-
Total Assets
$298,290
$604,986
+103%
Liabilities
2023
2024
Change
Payables & Accruals
$14,395
$30,992
+115%
Grants Payable
-
-
-
Deferred Revenue
$11,690
$12,468
+7%
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
-
-
-
Total Liabilities
$26,085
$43,460
+67%
Net assets
2023
2024
Change
Restricted Net Assets
$65,368
$46,969
-28%
Unrestricted Net Assets
$206,837
$514,557
+149%
Net assets
2023
2024
Change
Net assets
+$272,205
+$561,526
+106%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)